Quotient Sciences Acquires Arcinova

Read the press release here

Celebrating two years in business

Arcinova was launched in February 2016, following the acquisition of the Covance site in Alnwick, by Arc Trinova Limited, a new company formed by Ian Shott and Paul Ryan, owners of Shott Trinova LLP. Our site was formerly owned by Sanofi, before being bought by Covance in 2010.

Arcinova’s year on year turnover grew by 60 per cent and our client numbers have increased from 50 to more than 120 in less than 24 months. 

We have almost doubled our workforce in the last two years and have recently recruited new scientists into our Bioanalysis, API and CMC teams.

Our site has seen substantial additional investment since the launch of Arcinova as a company. We’ve invested heavily in new drug formulation and small volume API manufacturing equipment – including the introduction of two 20 litre capacity streams and one five litre stream - and we have extended our existing CMC and bioanalysis capabilities. 

Ian Shott, CEO of Arcinova said: “It’s heartening to see that in just two years, we’ve built on the experience of the site’s existing team and our world-class facilities in Alnwick to grow our workforce, extend our capabilities and further strengthen our ability to serve the global pharmaceutical and biotechnology communities. 

“Our specialist teams are making a real difference to drug development projects across the world and we are witnessing growing demand for our services. 

“It has been an exciting journey so far and we’re looking forward to what the future holds for Arcinova.” 

Read the full article online at the Chronicle Live

Discover how Arcinova can help

We provide a fully integrated approach to drug development, speak to our team and discover how we can help you fast forward to market.